Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gian Life Care's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.
Gian Life Care's long-term debt to total assets ratio
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Gian Life Care (BOM:542918) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Gian Life Care LT-Debt-to-Total-Asset Related Terms
Gian Life Care LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Gian Life Care's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gian Life Care (BOM:542918) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gian Life Care and its competitors.
Is Gian Life Care's LT-Debt-to-Total-Asset too high?
Gian Life Care's current LT-Debt-to-Total-Asset is 0.00. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's LT-Debt-to-Total-Asset compare to TMO and DHR?
Gian Life Care's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gian Life Care and its competitors. Gian Life Care's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.88, compared to a current price of ₹4.91 — trading 16.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.91 is trading 16.5% below its estimated GF Value™ of ₹5.88.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
LT-Debt-to-Total-Asset: 0.00
GF Value™: ₹5.88 vs. price of ₹4.91 (16.5% below fair value)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
